Patients with GBP5-high SCLC had highly expressed cytotoxicity, chemokines, antigen-presenting, and TNF family–related genes and higher proportion of responders to immunotherapy than those in the GBP5-low group (P < 0.05), indicating the potential of CBP5 to predict ICI efficacy for patients with SCLC (49). The gene discussed is GBP5; the disease is small cell lung carcinoma.